Biofrontera Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Biofrontera Inc. (BFRI) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $1.53 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-08-13
- Biofrontera Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-06-30 was $70.00K.
- Biofrontera Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-03-31 was $1.46M.
- Biofrontera Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $1.27M, a 4446.43% increase year-over-year.
- Biofrontera Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $0.00.
- Biofrontera Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $1.37M, a 2392.73% increase from fiscal 2024.
- Biofrontera Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $55.00K, a 93.13% decline from fiscal 2023.
- Biofrontera Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $800.00K, a 241.88% increase from fiscal 2022.
- Biofrontera Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $234.00K.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $70.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $1.53M 10-Q · filed 2026-08-13 | $2.80M derived: sum of 3 quarters · filed 2026-08-13 | $2.80M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $1.46M 10-Q · filed 2026-05-14 | $2.73M derived: sum of 2 quarters · filed 2026-05-14 | $2.73M derived: sum of 3 quarters · filed 2026-05-14 | |
| 2025-12-31 | $1.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $1.27M derived: sum of 2 quarters · filed 2026-03-19 | $1.37M 10-K · filed 2026-03-19 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $98.00K 10-Q · filed 2025-11-12 | ||
| 2025-06-30 | $98.00K 10-Q · filed 2026-08-13 | |||
| 2024-12-31 | $28.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $55.00K 10-K · filed 2026-03-19 | ||
| 2024-09-30 | $27.00K 10-Q · filed 2025-11-12 | |||
| 2023-12-31 | $653.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $800.00K 10-K · filed 2025-03-20 | ||
| 2023-09-30 | $147.00K 10-Q · filed 2024-11-14 | |||
| 2022-12-31 | $234.00K 10-K · filed 2024-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B |